OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goel on the Evolution of Precision and Personalized Medicine in Cancer Care

February 16th 2023

Sanjay Goel, MD, MS, discusses the evolution of precision and personalized medicine in cancer care.

Dr. Sidana on CAR T-cell Therapy in R/R Multiple Myeloma With Renal Impairment

February 16th 2023

Surbhi Sidana, MD, discusses the feasibility of administering idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma with renal impairment.

Dr. Shah on LV20.19 CAR T-cell Therapy in R/R MCL

February 16th 2023

Nirav N. Shah, MD, discusses findings from a phase 1/2 study of lentiviral bispecific CAR T cells targeting CD20 and CD19 B-cell antigens in patients with relapsed or refractory mantle cell lymphoma.

Dr. Kuykendall on the Investigation of Navitoclax Plus Ruxolitinib in Myelofibrosis

February 15th 2023

Andrew Kuykendall, MD, discusses the investigation of navitoclax plus ruxolitinib in myelofibrosis.

Dr. Dreyling on Key Safety Data from the TRIANGLE Trial in MCL

February 15th 2023

Martin Dreyling, MD, discusses the key safety data from the phase 3 TRIANGLE trial in younger patients with mantle cell lymphoma.

Dr. Costa on the Implications of the KEYNOTE-522 Trial in TNBC

February 15th 2023

Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.

Dr. Choudhury on The Need for Biomarkers to Predict Benefit With PARP Inhibitors in mCRPC

February 14th 2023

Atish D. Choudhury, MD, PhD, discusses the need for expanded genomic profiling and additional biomarkers to better predict which patients with metastatic castration-resistant prostate cancer could benefit from treatment with PARP inhibitor–based combinations.

Dr. Mukherjee on the Role of Disease Biology in the Treatment of MCL

February 14th 2023

Akash Mukherjee, MD, discusses the importance of understanding disease biology when attempting to individualize treatment approaches in mantle cell lymphoma.

Dr. Rini on the Current Standard of Care in R/R RCC

February 14th 2023

Brian I. Rini, MD, FASCO, discusses the current treatment landscape for patients with relapsed/refractory renal cell carcinoma.

Dr. Berg on Key Ongoing Trials in Metastatic Urothelial Carcinoma

February 14th 2023

Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.

Dr. Patel on Post-ASCT Complications in Myelofibrosis

February 14th 2023

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

Dr. Phillips on the Early Implications of Glofitamab Monotherapy in R/R MCL

February 13th 2023

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

February 13th 2023

Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Dr. Fecteau on the Benefit of a Multidisciplinary Approach in Bladder and Prostate Cancers

February 13th 2023

Ryan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.

Dr. Kim on the Synergistic Effect of PD-1H Blockade in AML

February 13th 2023

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Dr. Goy on Durable Responses With Brexu-cel in the ZUMA-2 Trial in MCL

February 13th 2023

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Haffner Outlines the Unique Genomics of Basal Cell Carcinoma

February 13th 2023

Michael C. Haffner, MD, PhD, explains the genomic differences between prostate adenocarcinoma of the prostate and prostatic basal cell carcinoma, an extremely rare disease.

Dr. Blum on Potential of CA-125 as a Biomarker for Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.

Dr. Blum Discusses Survival Outcomes for Patients With Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, says that patients with renal medullary carcinoma have poor prognosis, but anecdotal evidence suggests that survival outcomes may be improving.

Dr. Blum Discusses the Challenges of Diagnosing Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, discusses how few physicians have experience with renal medullary carcinoma, and the disease often presents with nonspecific symptoms.